Last reviewed · How we verify
Alprostadil Liposomes for Injection
vasodilation via prostaglandin E1 receptor agonism
vasodilation via prostaglandin E1 receptor agonism Used for Pulmonary hypertension, Cerebral vasospasm.
At a glance
| Generic name | Alprostadil Liposomes for Injection |
|---|---|
| Also known as | No other names |
| Sponsor | Guangzhou Yipinhong Pharmaceutical CO.,LTD |
| Drug class | vasodilator |
| Target | prostaglandin E1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Alprostadil is a synthetic form of prostaglandin E1, which stimulates the vasodilation of blood vessels.
Approved indications
- Pulmonary hypertension
- Cerebral vasospasm
Common side effects
- Flushing
- Hypotension
- Pain at injection site
Key clinical trials
- A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (PHASE2)
- Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran (PHASE2)
- The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers (PHASE1)
- A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans (PHASE2)
- The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: